Genome-wide association study of antipsychotic-induced QTc interval prolongation

Pharmacogenomics Journal

Volumn 12, Issue 2, 2012, Pages 165-172

  Aberg K ^a   Adkins, D E ^a   Liu, Y ^b   McClay, J L ^a   Bukszar J ^a   Jia, P ^c   Zhao, Z ^c   Perkins, D ^b   Stroup, T S ^d   Lieberman, J A ^d   Sullivan, P F ^b,e   Van Den Oord, E J C G ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Howard Hughes Medical Institute   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

adverse effects; candidate gene analysis; CATIE; genome wide association study; schizophrenia

Indexed keywords

OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; FEMALE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; NOS1AP GENE; NUBPL GENE; PRIORITY JOURNAL; QT PROLONGATION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A23 GENE;

ADULT; ANTIPSYCHOTIC AGENTS; ELECTROCARDIOGRAPHY; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84858999530     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.76     Document Type: Article

References (40)

1. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003; 45: 415-427. (Pubitemid 36403114)
2. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003; 82: 282-290. (Pubitemid 36859224)
3. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161-1167. (Pubitemid 33121508)
4. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19: 287-302. (Pubitemid 23183149)
5. Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet 1995; 346: 820-825.
6. Glassman AH, Bigger Jr JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782. (Pubitemid 33054769)
7. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003; 107: 85-95. (Pubitemid 36164475)
8. Yerrabolu M, Prabhudesai S, Tawam M, Winter L, Kamalesh M. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis 2000; 2: 10-12.
9. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004; 82: 182-188. (Pubitemid 38392168)
10. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 2006; 38: 644-651. (Pubitemid 43927305)
11. Aarnoudse AJ, Newton-Cheh C, de Bakker PI, Straus SM, Kors JA, Hofman A et al. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation 2007; 116: 10-16. (Pubitemid 47016241)
12. Post W, Shen H, Damcott C, Arking DE, Kao WH, Sack PA et al. Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish. Hum Hered 2007; 64: 214-219. (Pubitemid 47036984)
13. Tobin MD, Kahonen M, Braund P, Nieminen T, Hajat C, Tomaszewski M et al. Gender and effects of a common genetic variant in the NOS1 regulator NOS1AP on cardiac repolarization in 3761 individuals from two independent populations. Int J Epidemiol 2008; 37: 1132-1141.
14. Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, Fuchsberger C et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet 2009; 41: 407-414.
15. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet 2009; 41: 399-406.
16. Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009; 14: 1024-1031.
17. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223. (Pubitemid 41345943)
18. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15-31. (Pubitemid 36871054)
19. First MB, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM IV Axis I Disorders - Administration Booklet. American Psychiatric Press, Inc.: Washington D.C.:, 1994.
20. Bazett H. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-370.
21. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008; 13: 570-584. (Pubitemid 351704941)
22. van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res 2009; 107: 13-21.
23. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, Miller del D et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279-282.
24. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2009; e-pub ahead of print 1 September 2009; doi:10.1038/mp.2009.89.
25. Goldstein H. Multilevel statistical models. Arnold: London, 1995.
26. Searle SR, Casella G, McCulloch CE. Variance components. Wiley: New York, 1992.
27. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-Plus. Springer: New York, NY, 2000.
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575. (Pubitemid 47330214)
29. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909. (Pubitemid 44141658)
30. Storey JD. The positive false discovery rate: A Bayesian interpretation and the q-value. Annals of Statistics 2003; 31: 2013-2035. (Pubitemid 38293903)
31. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445. (Pubitemid 37033947)
32. van den Oord EJ, Sullivan PF. False discoveries and models for gene discovery. Trends Genet 2003; 19: 537-542. (Pubitemid 37204912)
33. Bukszar J, McClay J, van den Oord E. Estimating the posterior probability that genomewide association findings are true or false. Bioinformatics 2009, Jul 14.
34. Glonek G, Soloman P. Discussion of resampling-based multiple testing for microarray data analysis by ge, dudoit and speed. Test 2003; 12: 1-77. (Pubitemid 36964087)
35. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9-39. (Pubitemid 35264999)
36. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999; 55: 997-1004.
37. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch 2004; 447: 666-676. (Pubitemid 38241452)
38. Jacobsson JA, Haitina T, Lindblom J, Fredriksson R. Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family. Genomics 2007; 90: 595-609. (Pubitemid 350016717)
39. Christoforou N, Miller RA, Hill CM, Jie CC, McCallion AS, Gearhart JD. Mouse ES cell-derived cardiac precursor cells are multipotent and facilitate identification of novel cardiac genes. J Clin Invest 2008; 118: 894-903. (Pubitemid 351364597)
40. Chang KC, Barth AS, Sasano T, Kizana E, Kashiwakura Y, Zhang Y et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc Natl Acad Sci USA 2008; 105: 4477-4482. (Pubitemid 351754405)